Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma
Jens Bauer, Natalie Köhler, Yacine Maringer, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 36

Showing 1-25 of 36 citing articles:

Antigen presentation in cancer — mechanisms and clinical implications for immunotherapy
Kailin Yang, Ahmed Halima, Timothy A. Chan
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 9, pp. 604-623
Closed Access | Times Cited: 100
Workflow enabling deepscale immunopeptidome, proteome, ubiquitylome, phosphoproteome, and acetylome analyses of sample-limited tissues
Jennifer G. Abelin, Erik J. Bergstrom, Keith Rivera, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 35
A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma
Alireza Tojjari, Ahmed Saeed, Meghana Singh, et al.
Vaccines (2023) Vol. 11, Iss. 8, pp. 1357-1357
Open Access | Times Cited: 26
Co-Reactive Ligand In Situ Engineered Gold Nanoclusters with Ultra-Bright Near-Infrared Electrochemiluminescence for Ultrasensitive and Label-Free Detection of Carboxylesterase Activity
Wenzheng Guo, Mingyang Xia, Peng Duan, et al.
Analytical Chemistry (2024) Vol. 96, Iss. 6, pp. 2369-2377
Closed Access | Times Cited: 7
TOFIMS mass spectrometry-based immunopeptidomics refines tumor antigen identification
Naomi Hoenisch Gravel, Annika Nelde, Jens Bauer, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 17
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells
Annika Nelde, Heiko Schuster, Jonas S. Heitmann, et al.
Blood Cancer Discovery (2023) Vol. 4, Iss. 6, pp. 468-489
Open Access | Times Cited: 16
How Do I Diagnose Fibrolamellar Carcinoma?
Haukur Einarsson, Rondell P. Graham
Modern Pathology (2025), pp. 100711-100711
Closed Access
S3-Leitlinie Diagnostik und Therapie biliärer Karzinome – Langversion
Sabrina Groß, Michael Bitzer, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 02, pp. e82-e158
Closed Access
Fibrolamellar Hepatocellular Carcinoma
Yasuyuki Shigematsu, Kazuhito Tanaka, Kentaro Inamura
Internal Medicine (2025)
Open Access
S3-Leitlinie Diagnostik und Therapie des Hepatozellulären Karzinoms – Langversion
Michael Bitzer, Sabrina Groß, Jörg Albert, et al.
Zeitschrift für Gastroenterologie (2025) Vol. 63, Iss. 03, pp. e159-e260
Closed Access
Current perspectives on mass spectrometry-based immunopeptidomics: the computational angle to tumor antigen discovery
Bing Zhang, Michal Bassani‐Sternberg
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 10, pp. e007073-e007073
Open Access | Times Cited: 13
Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma
Sanford M. Simon
Nature reviews. Cancer (2023) Vol. 23, Iss. 5, pp. 335-346
Open Access | Times Cited: 12
Immunotherapy in liver cancer: overcoming the tolerogenic liver microenvironment
Yanju Liu, Hongyuan Yang, Tian Li, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 4
Reversing immunosuppression in the tumor microenvironment of fibrolamellar carcinoma via PD-1 and IL-10 blockade
Sara K. Daniel, Kevin M. Sullivan, Lindsay K. Dickerson, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma
Allison M. Kirk, Jeremy Chase Crawford, Ching‐Heng Chou, et al.
Cell Reports Medicine (2024) Vol. 5, Iss. 3, pp. 101469-101469
Open Access | Times Cited: 3
Rare primary liver cancers: An EASL position paper
Henning Wege, Claudia Campani, Ruben H. de Kleine, et al.
Journal of Hepatology (2024) Vol. 81, Iss. 4, pp. 704-725
Closed Access | Times Cited: 2
FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion
Christopher Hackenbruch, Jens Bauer, Jonas S. Heitmann, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
iVAC-XS15-CLL01: personalized multi-peptide vaccination in combination with the TLR1/2 ligand XS15 in CLL patients undergoing BTK-inhibitor-based regimens
Alexander Englisch, Clara Hayn, Susanne Jung, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
MiR‐23a‐3p alleviates cigarette smoke extract‐induced pulmonary vascular endothelial cell apoptosis by targeting DNAJB1 in emphysema
Ke Li, Xianwei Ye, Mei Xu, et al.
The Clinical Respiratory Journal (2023) Vol. 17, Iss. 12, pp. 1223-1232
Open Access | Times Cited: 3
Downregulated RBM5 Enhances CARM1 Expression and Activates the PRKACA/GSK3β Signaling Pathway through Alternative Splicing-Coupled Nonsense-Mediated Decay
Yanping Zhang, Fang Li, Zhenwei Han, et al.
Cancers (2023) Vol. 16, Iss. 1, pp. 139-139
Open Access | Times Cited: 3
CDK7 is a Novel Therapeutic Vulnerability in Fibrolamellar Carcinoma
Manabu Nukaya, Crystal Cafferty, Katerina Zahed, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
The Novel-B-Cell-Related Gene Signature Predicts the Prognosis and Immune Status of Patients with Esophageal Carcinoma
Xinhong Li, Tongyu Sun, Hongyan Li, et al.
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 3, pp. 1313-1323
Open Access
Diagnosis and Molecular Characterization of Potential RNA Binding Protein Involved in the Pathogenesis of Liver Ischemia Reperfusion Injury
Weiju Lai, Jiajian Yu, Diguang Wen
Journal of Inflammation Research (2024) Vol. Volume 17, pp. 4881-4893
Open Access
Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without mTOR Inhibitors in Patients with Fibrolamellar Carcinoma
Ghassan K. Abou‐Alfa, Tim Meyer, Richard Kinh Gian, et al.
Liver Cancer (2024), pp. 1-10
Open Access
Aggressive Surgical Management of Bilateral Metachronous Lung Metastases in Fibrolamellar Hepatocellular Carcinoma, a Case Report
Samuele Nicotra, Luca Melan, Alberto Giovanni Busetto, et al.
Livers (2024) Vol. 4, Iss. 3, pp. 398-405
Open Access
Page 1 - Next Page

Scroll to top